SiBionics and PharmaSens Explore Automated Insulin Delivery
SiBionics presented new technology linking continuous glucose monitoring with automated insulin delivery at the EASD 2026 congress. The exploration with PharmaSens aims to advance diabetes management.
SiBionics unveiled new diabetes management technology at the European Association for the Study of Diabetes (EASD) congress 2026. The system, branded "See More, Act Earlier," integrates continuous glucose monitoring (CGM) with automated insulin delivery. The goal is to enhance the quality of life for individuals with diabetes by enabling quicker responses to blood sugar fluctuations.
The technology utilizes CGM data to predict glycemic changes and automatically adjust insulin dosage. This proactive approach aims to reduce the reliance on manual diabetes management and stabilize blood sugar levels, potentially preventing long-term complications.
The company has also indicated a research collaboration with PharmaSens. While specific details of this partnership remain undisclosed, it suggests a commitment to developing more integrated and efficient solutions for insulin delivery and diabetes control. Such advancements could significantly alter future diabetes treatment paradigms.
The EASD congress served as a venue to showcase these technological strides to medical professionals. SiBionics aims to bring solutions to market that make managing diabetes a more seamless and less burdensome experience for patients.